Genetics & Stem Cells News

Medindia's Press Release’ section provides the latest press release on Genetics & Stem Cells from across the world for the global audience. This page links to 1799 Genetics & Stem Cells press releases.

Children's Mercy Kansas City and Geneyx Inc. Announce Collaboration to Advance Genomic Research and Analysis

KANSAS CITY, Mo. and WILMINGTON, Del. , March 13, 2024 /PRNewswire/ -- Children's Mercy Kansas City, one of the leading independent pediatric health organizations, and  Geneyx  Inc. are pleased to announce a collaboration aimed at ...


Korea University College of Medicine Identifies Hantavirus in South Korea Using a New Rapid Test, Paving Way for Early Outbreak Control

Research unveils cost-efficient Flongle sequencing's potential for rapid hantavirus genome-based diagnostics and phylogeographical surveillance SEOUL, South Korea , Feb. 29, 2024 /PRNewswire/ -- Orthohantaviruses, highly transmissible ...

Novotech Publishes Duchenne Muscular Dystrophy Landscape Report to Support Biotech Research Planning

BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Novotech , the global full-service clinical Contract Research Organization (CRO) that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, ...

Kanazawa University research: Chromatin Accessibility: A new avenue for gene editing

KANAZAWA, Japan , Feb. 16, 2024 /PRNewswire/ -- In a study recently published in  Nature Genetics, researchers from Nano Life Science Institute (WPI-NanoLSI), Kanazawa University explore chromatin accessibility, i.e., endogenous access ...

Juntendo University Broadens the Scope of Mitochondrial Disease Testing

The Intractable Disease Research Center at Juntendo University will conduct broader analyses of mitochondrial genetic data to confirm genetic diagnosis. TOKYO , Feb. 12, 2024 /PRNewswire/ -- Mitochondrial disease occurs when ...

Rebirth Clinics Launches State-of-the-Art Stem Cell Centers in Abu Dhabi and Dubai

Leading Regenerative Medicine, Rebirth Clinics Brings Innovative Stem Cell and Anti-Aging Therapies to the UAE HONG KONG , Feb. 1, 2024 /PRNewswire-PRWeb/ -- Rebirth Clinics , a global leader in regenerative medicine products and ...

Vivet Therapeutics receives EUR 4.9 million to advance development of a gene therapy for the treatment of cerebrotendinous xanthomatosis

Funding from French Government as part of the France Health Innovation Plan 2030 operated by Bpifrance  PARIS , Feb. 1, 2024 /PRNewswire/ -- Vivet Therapeutics ("Vivet"), a clinical stage biotech company developing novel and ...

Singleron launches the AccuraSCOPE® Single Cell Transcriptome

COLOGNE, Germany , Jan. 30, 2024 /PRNewswire/ -- Singleron Biotechnologies, a leader in single cell multi-omic solutions for precision medicine, announced two new commercial product launches : AccuraSCOPE ® Single Cell Transcriptome ...

Ractigen Therapeutics Enters Strategic Partnership with University Medical Center Utrecht to Drive saRNA Innovation in Neurodevelopmental Disorders

SUZHOU, China , Jan. 29, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company leading the charge in small activating RNA (saRNA) therapeutics, announces a formal collaboration with University Medical Center ...

AbbVie and Umoja Biopharma Announce Strategic Collaboration to Develop Novel In-Situ CAR-T Cell Therapies

Collaboration to leverage Umoja's VivoVec TM gene delivery platform and AbbVie's expertise in oncology to develop in-situ generated chimeric antigen receptor (CAR)-T cell therapy candidates NORTH CHICAGO, Ill. and SEATTLE , Jan. 4, ...

Genetics & Stem Cells News »

Over 275 Million Genetic Variants Unlock the Key to Health Mysteries

Over 275 Million Genetic Variants Unlock the Key to Health Mysteries

Researchers from the National Institutes of Health (NIH), US have identified over 275 million genetic variants that were not previously reported. This undiscovered pool of variants opens up new avenues for comprehending the genetic factors impacting ...

New Gene Therapy for Children With Genetic Epilepsy

New Gene Therapy for Children With Genetic Epilepsy

CDD - CDKL5 deficiency disorder, a most common type of genetic epilepsy in children, occurs due to the loss of genes producing the CDKL5 enzyme. Scientists at the Francis Crick...

Gene Dyrk1a Linked to Heart Defects in Down Syndrome Identified

Gene Dyrk1a Linked to Heart Defects in Down Syndrome Identified

Leveraging genetic mapping, scientists pinpointed a gene on human chromosome 21 named Dyrk1a. In the mouse model of Down syndrome , having three copies of this gene leads to heart defects . While Dyrk1a has been associated with cognitive impairment and facial changes in Down syndrome, its involvement in heart development was previously unknown. ( ) Down syndrome affects around 1 in 800 new births and is caused by an extra third copy of chromosome 21. About half of babies born with Down syndrome have heart defects, such as a failure of the heart to separate into four chambers, leaving a ‘hole in the heart’. If the heart defects are very serious, high-risk surgery might be needed soon after birth and people often require ongoing monitoring of the heart for the rest of their life. Therefore, better treatment options are needed and this must be guided by knowledge of which of the extra 230 genes on chromosome 21 are responsible for the heart defects. But before this study the identity of these causative genes was not known. In research published today in Science Translational Medicine , the team at the Crick and UCL studied human Down syndrome fetal hearts as well as embryonic hearts from a mouse model of Down syndrome. An extra copy of Dyrk1a turned down the activity of genes required for cell division in the developing heart and the function of the mitochondria, which produce energy for the cells. These changes correlated with a failure to correctly separate the chambers of the heart. Unveiling the Missing Link in Down Syndrome Heart Defects The team found that while Dyrk1a is required in three copies to cause heart defects in mice, it was not sufficient alone. Thus, another unknown gene must also be involved in the origin of heart defects in Down syndrome. The team is currently searching for this second gene. Dyrk1a codes for an enzyme called DYRK1A. The researchers tested a DYRK1A inhibitor on mice pregnant with pups that model the hearts defects in Down syndrome, as their hearts were forming. When DYRK1A was inhibited, the genetic changes were partially reversed and the heart defects in the pups were less severe. Victor Tybulewicz, Group Leader of the Immune Cell Biology Laboratory & Down Syndrome Laboratory, said: “Our research shows that inhibiting DYRK1A can partially reverse changes in mouse hearts, suggesting that this may be a useful therapeutic approach. “However, in humans the heart forms in the first 8 weeks of pregnancy, likely before a baby could be screened for Down syndrome, so this would be too early for treatment. The hope is that a DYRK1A inhibitor could have an effect on the heart later in pregnancy, or even better after birth. These are possibilities we are currently investigating.” This research forms part of the lab’s overall goal to understand the genetics behind all aspects of Down syndrome. Eva Lana-Elola, Principal Laboratory Research Scientist at the Crick, and co-first author, said: “It was remarkable that just restoring the copy number of one gene from 3 to 2 reversed the heart defects in the mouse model for Down syndrome. We’re now aiming to understand which of the other genes on this extra chromosome are involved. Even though Dyrk1a isn’t the only gene involved, it’s clearly a major player in many different aspects of Down syndrome.” Rifdat Aoidi, Postdoctoral Project Research Scientist at the Crick, and co-first author, said: “We don’t yet know why the changes in cell division and mitochondria mean the heart can’t correctly form chambers. Dysfunction in the mitochondria has also been linked to cognitive impairment in Down syndrome, so boosting mitochondrial function could be another promising avenue for therapy.” Reference: Increased dosage of DYRK1A leads to congenital heart defects in a mouse model of Down syndrome - (https:...

New Tool Enhances Precision in Uncovering Disease-Causing Genes

New Tool Enhances Precision in Uncovering Disease-Causing Genes

Researchers have introduced an innovative statistical tool enhancing the identification of disease-causing genetic variants. This tool combines information from genome-wide association studies (GWAS) with predictions of genetic expression, ...

Mapping Genetic Mutations to Customize Preterm Birth Therapy

Mapping Genetic Mutations to Customize Preterm Birth Therapy

Pregnant women with high levels of certain genetic mutations– especially those associated with involuntary muscle contraction – were less likely to respond to preterm treatment. Screening for genetic mutations could allow doctors to tailor effective ...

More Genetics & Stem Cells News

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.